Study guide

13.1 The Well-Woman Visit & Cervical Cancer Screening

AMCB Certified Nurse-Midwife CNM

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Early Pregnancy — Diagnosis, History, Dating & Models of Care

1.1 Signs of Pregnancy, hCG Kinetics & Acceptance of Pregnancy 1.2 Prenatal History, Obstetric Notation & Gestational Dating 1.3 The Initial Prenatal Laboratory Panel 1.4 Prenatal Genetic Screening, Diagnostic Testing & Hereditary Risk 1.5 Models of Prenatal Care, Birth-Setting Counseling & Community Referral

2 Chapter 2: Ongoing Prenatal Assessment, Nutrition & Common Discomforts

2.1 Prenatal Visit Cadence, Milestone Screening & Fundal Height 2.2 Leopold Maneuvers, Fetal Heart Auscultation & Antepartum Surveillance 2.3 Clinical Pelvimetry & Assessment of the Bony Pelvis 2.4 Maternal Nutrition, Weight Gain & Immunization in Pregnancy 2.5 Nausea, Vomiting & Gastrointestinal Discomforts of Pregnancy 2.6 Musculoskeletal, Vascular & Neurologic Discomforts of Pregnancy

3 Chapter 3: Hypertensive, Endocrine & Hematologic Complications of Pregnancy

3.1 Classification & Diagnosis of Hypertensive Disorders of Pregnancy 3.2 Acute Severe Hypertension, Magnesium Sulfate & Eclampsia 3.3 Delivery Timing, Aspirin Prophylaxis & Postpartum Hypertension 3.4 Gestational Diabetes: Pathophysiology, Screening & Diagnosis 3.5 Glycemic Management, Fetal Surveillance & Delivery Timing in Gestational Diabetes 3.6 Thyroid Disorders & Anemia in Pregnancy

4 Chapter 4: Bleeding, Amniotic Fluid Disorders, Preterm Birth & Perinatal Loss

4.1 First-Trimester Bleeding, Early Pregnancy Loss & Gestational Trophoblastic Disease 4.2 Ectopic Pregnancy: Diagnosis & Management 4.3 Third-Trimester Bleeding & Amniotic Fluid Volume Disorders 4.4 Preterm Labor & Preterm Prelabor Rupture of Membranes 4.5 Intrauterine Fetal Demise, Stillbirth & Bereavement Care

5 Chapter 5: Normal Labor, Birth & Intrapartum Fetal Surveillance

5.1 Onset of Labor, True Versus False Labor & Nutrition in Labor 5.2 The First and Second Stages of Labor 5.3 Cardinal Movements, Third & Fourth Stages of Labor 5.4 Cord Clamping, Cord Blood, Cord Gases & Placental Examination 5.5 Fetal Oxygenation, Intermittent Auscultation & Uterine Activity Monitoring 5.6 Electronic Fetal Monitoring Parameters & the NICHD Categories 5.7 Intrauterine Resuscitation, Scalp Electrode & Amnioinfusion

6 Chapter 6: Labor Support, Analgesia, Induction & Augmentation

6.1 The Midwifery Model, Continuous Labor Support & Non-Pharmacologic Comfort 6.2 Water Immersion, Waterbirth & Non-Supine Birth Positions 6.3 Systemic, Neuraxial & Regional Analgesia in Labor 6.4 Indications & Timing for Induction of Labor 6.5 The Bishop Score & Cervical Ripening Methods 6.6 Oxytocin Titration, Tachysystole Management & Amniotomy

7 Chapter 7: Intrapartum Emergencies, Malpresentation & Perineal Repair

7.1 Shoulder Dystocia: Recognition & the HELPERR Protocol 7.2 Dystocia Complications, Umbilical Cord Prolapse & Intraamniotic Infection 7.3 Malposition, Manual Rotation, Breech, Face Presentation & Nuchal Cord 7.4 Perineal Anatomy & Classification of Obstetric Lacerations 7.5 Episiotomy & Surgical Perineal Repair 7.6 TOLAC, VBAC & Uterine Rupture

8 Chapter 8: The Normal Puerperium, Postpartum Assessment & Lactation

8.1 Puerperal Physiology, Uterine Involution & Lochia 8.2 The BUBBLE-HE Postpartum Assessment 8.3 Bladder, Bowel & Perineal Care and the Postpartum Care Continuum 8.4 Lactation Neuroendocrinology & the Stages of Lactogenesis 8.5 LATCH Assessment, Latch Biomechanics & Adequate Intake 8.6 Lactation Complications, Medication Safety & Contraindications

9 Chapter 9: Postpartum Contraception, Family Planning & Hemorrhage

9.1 Return of Fertility, Lactational Amenorrhea & US MEC in the Puerperium 9.2 Postpartum Hormonal Contraception & Intrauterine Devices 9.3 Barrier & Permanent Contraception, Postpartum Sexuality & Family Support 9.4 Postpartum Hemorrhage: Definition, Shock Recognition & Quantitative Blood Loss 9.5 The Four Ts: Etiology of Postpartum Hemorrhage 9.6 Hemorrhage Resuscitation, Uterotonics, TXA & Surgical Escalation

10 Chapter 10: Puerperal Infection, Thromboembolism, Cesarean Recovery & Perinatal Mental Health

10.1 Puerperal Endometritis & Septic Pelvic Thrombophlebitis 10.2 Puerperal Wound Infection, Mastitis & Breast Abscess 10.3 Postpartum Venous Thromboembolism 10.4 Post-Cesarean Recovery: Inpatient Care & Care After Discharge 10.5 Postpartum Blues, Depression & EPDS Screening 10.6 Treating Postpartum Depression, Anxiety, OCD & Psychosis

11 Chapter 11: Neonatal Transition, Resuscitation & the Newborn Examination

11.1 Fetal-to-Neonatal Transition & Circulatory Remodeling 11.2 APGAR Scoring & the NRP Initial Steps 11.3 Positive Pressure Ventilation, MR. SOPA & Advanced Resuscitation 11.4 Newborn Vital Signs, Anthropometrics & the Ballard Score 11.5 Cranial Assessment & Head-to-Chest Examination 11.6 Genitourinary & Musculoskeletal Examination and Primitive Reflexes

12 Chapter 12: Newborn Prophylaxis, Screening, Common Disorders & Care Through 28 Days

12.1 Standard Neonatal Prophylaxis: Vitamin K, Eye Ointment & Hepatitis B 12.2 Universal Newborn Screening: Hearing, CCHD & Dried Blood Spot 12.3 Neonatal Hypoglycemia, Thermoregulation & the Infant of a Diabetic Mother 12.4 Neonatal Hyperbilirubinemia & Phototherapy 12.5 Infant Feeding Education, Circumcision Counseling & Care Through 28 Days

13 Chapter 13: Well-Woman Preventive Care, Cancer Screening & Immunization

13.1 The Well-Woman Visit & Cervical Cancer Screening 13.2 ASCCP Risk-Based Management & Breast Cancer Screening 13.3 Colorectal Cancer & Osteoporosis Screening 13.4 Adult Immunization & Environmental and Occupational Exposure Screening

14 Chapter 14: Contraception, Abortion Care & Fertility Evaluation

14.1 Contraceptive Efficacy Tiers & Long-Acting Reversible Contraception 14.2 Combined Hormonal Contraception 14.3 Progestin-Only Methods & Emergency Contraception 14.4 Abortion Care: Options Counseling, Medication Abortion & Follow-Up 14.5 Initial Infertility Evaluation & Gynecologic Imaging Referral

15 Chapter 15: Benign Gynecologic Conditions, Pelvic Floor & Menstrual Disorders

15.1 Endometriosis & Adenomyosis 15.2 Pelvic Organ Prolapse & Urinary Incontinence 15.3 Adnexal Masses, Malignancy Red Flags & Vulvar Disease 15.4 The Normal Menstrual Cycle & Anticipatory Guidance 15.5 The FIGO PALM-COEIN Classification of Abnormal Uterine Bleeding 15.6 Evaluating Abnormal Uterine Bleeding & the Amenorrhea Workup 15.7 Polycystic Ovary Syndrome

16 Chapter 16: Vaginitis, Sexually Transmitted Infections, Sexual Health & Menopause

16.1 Differential Diagnosis of Vaginitis & Bacterial Vaginosis 16.2 Candidiasis, Trichomoniasis, Chlamydia & Gonorrhea 16.3 Pelvic Inflammatory Disease 16.4 Genital Herpes, Syphilis & Anogenital Warts 16.5 Sexual Health Assessment, Sexual Function & Care After Sexual Assault 16.6 Reproductive Aging, Menopause Definitions & Clinical Manifestations 16.7 Menopausal Hormone Therapy 16.8 Non-Hormonal Therapies & Postmenopausal Osteoporosis

17 Chapter 17: Primary Care — Chronic Disease & Common Acute Conditions

17.1 Midwifery Primary Care Scope & Hypertension Management 17.2 Antihypertensive Pharmacotherapy & Hyperlipidemia 17.3 Type 2 Diabetes & Thyroid Disease in Primary Care 17.4 Respiratory Infections, Asthma & Urinary Tract Infection 17.5 Gastrointestinal & Dermatologic Conditions 17.6 Mental Health Screening & Substance Use Disorders 17.7 Intimate Partner Violence, Reproductive Coercion & Human Trafficking

18 Chapter 18: Midwifery Scope of Practice, Ethics, Collaboration & Health Equity

18.1 Regulatory Foundation of Practice & the Midwifery Model of Care 18.2 Bioethics, Informed Refusal & Collaborative Practice 18.3 Maternal Health Disparities, Structural Racism & Inclusive Care

13.1 The Well-Woman Visit & Cervical Cancer Screening

Key Takeaways Explain This Topic AI

Cervical cancer screening is not recommended before age 21 regardless of sexual debut, because transient HPV infection is common and treatment of benign changes causes preterm birth.

From 21 to 29 years, cytology alone every 3 years is recommended and HPV testing is not, because high HPV prevalence drives unnecessary colposcopy.

From 30 to 65 years, acceptable strategies are cytology every 3 years, primary high-risk HPV testing every 5 years, or co-testing every 5 years.

Screening may stop after 65 with 3 consecutive negative cytology results or 2 consecutive negative co-tests in the past 10 years, the most recent within 5 years.

A history of CIN 2 or higher requires continued surveillance for at least 25 years, even beyond age 65 or after total hysterectomy.

Last updated: September 2026

The annual well-woman visit represents the cornerstone of preventive healthcare in midwifery practice. Grounded in the midwifery model of care, the well-woman encounter transcends episodic symptom management to provide holistic, lifespan-oriented health promotion, shared clinical decision-making, and evidence-based disease prevention. For the certified nurse-midwife (CNM), mastering the national screening guidelines established by the United States Preventive Services Task Force (USPSTF), the American Society for Colposcopy and Cervical Pathology (ASCCP), the American College of Obstetricians and Gynecologists (ACOG), and the Advisory Committee on Immunization Practices (ACIP) is essential for clinical excellence and success on the AMCB certification examination.

Well-Woman Annual Visit Architecture & Lifespan Preventive Care

The annual preventive visit is structured around a comprehensive clinical history, targeted health behavior counseling, an individualized, trauma-informed physical examination, and age-specific diagnostic screening. Rather than relying on a rigid, one-size-fits-all examination, modern guidelines emphasize personalized care tailored to age, reproductive life goals, medical and family pedigree, and individualized risk factors.

Core Components of the Well-Woman History

Gynecologic & Menstrual History: Menarche, cycle interval (normal 24 to 38 days), cycle regularity, duration of bleeding (normal ≤8 days), volume of flow, presence of severe dysmenorrhea, molimina symptoms, and date of the last menstrual period (LMP). In perimenopausal and postmenopausal women, evaluate bleeding patterns, vasomotor symptoms, and genitourinary symptoms of menopause.

Obstetric History: Detailed GP (Gravida/Para) and FPAL (Full-term, Preterm, Abortions [spontaneous/induced], Living children) score, route of birth, gestational age at birth, infant birth weights, and obstetric complications (preeclampsia, gestational diabetes, postpartum hemorrhage).

Sexual History (The "5 Ps"):

Partners: Number, gender(s), and duration of sexual partnerships.

Practices: Specific sexual activities (vaginal, anal, oral), barrier device utilization, and presence of sexual pain or dysfunction.

Prevention of STIs: Consistent condom use, history of pre-exposure prophylaxis (PrEP) if indicated.

Past History of STIs: Prior episodes of Chlamydia trachomatis , Neisseria gonorrhoeae , syphilis, herpes simplex virus (HSV), trichomoniasis, or pelvic inflammatory disease (PID).

Pregnancy Intentions: One Key Question ("Would you like to become pregnant in the next year?") to anchor reproductive life planning and contraceptive or pre-conception counseling.

Psychosocial & Safety Screenings:

Intimate Partner Violence (IPV): Universal screening for all adolescent and adult women utilizing validated tools such as the HITS screening instrument (Hurt, Insult, Threaten, Scream) or direct, private questioning.

Mental Health: Universal screening for major depressive disorder using the Patient Health Questionnaire-2 (PHQ-2), escalating to the PHQ-9 if positive; screening for generalized anxiety using the GAD-7.

Substance Use: Universal screening using the Screening, Brief Intervention, and Referral to Treatment (SBIRT) framework for tobacco, alcohol (AUDIT-C), cannabis, and illicit substances.

Social Determinants of Health (SDOH): Assessment of housing stability, food insecurity, economic security, transportation access, and systemic barriers to care.

The Physical Examination: Evidence-Based Indications

Historically, an annual bimanual pelvic examination, speculum examination, and clinical breast examination were considered mandatory components of every well-woman visit. Current evidence-based guidelines from the USPSTF, ACOG, and the American College of Physicians (ACP) clarify that routine, asymptomatic screening pelvic examinations in non-pregnant, non-symptomatic individuals do not reduce morbidity or mortality from ovarian, uterine, or other pelvic malignancies and are associated with false-positive findings, unnecessary surgery, and patient anxiety.

Indications for Pelvic Examination: Cervical cancer screening at designated age intervals, evaluation of abnormal uterine bleeding, investigation of acute or chronic pelvic pain, evaluation of pelvic organ prolapse or incontinence, suspected pelvic masses, evaluation of vulvovaginal symptoms or infectious discharge, and prior to insertion of an intrauterine device (IUD).

Asymptomatic Shared Decision-Making: For asymptomatic women aged 21 and older presenting for an annual visit when cervical cancer screening is not due, the decision to perform an internal bimanual pelvic examination should be made collaboratively between the woman and her midwife through shared decision-making.

Cervical Cancer Screening Guidelines: USPSTF & ASCCP Framework

Cervical cancer screening is one of the most successful public health initiatives in modern medicine, reducing cervical cancer incidence and mortality by more than 75%. Cervical carcinogenesis is almost universally driven by persistent infection with oncogenic high-risk Human Papillomavirus (hrHPV) genotypes. Over 90% of incident HPV infections in young individuals are transient and cleared effectively by cell-mediated host immunity within 12 to 24 months without causing neoplastic progression.

Cervical Screening Intervals Across the Lifespan

Age Group Recommended Screening Strategy Testing Interval Clinical Rationale & High-Yield Caveats

<21 Years NO SCREENING RECOMMENDED None Screening is strictly not recommended regardless of age at sexual debut or risk behaviors. High rate of transient HPV infections that resolve spontaneously. Treatment of benign cytologic changes causes cervical incompetence and preterm birth.

21 to 29 Years Cervical Cytology Alone (Pap smear) Every 3 Years Liquid-based or conventional cytology alone. hrHPV testing (primary or co-testing) is NOT recommended in this cohort because high HPV prevalence triggers excessive colposcopies and biopsies without reducing cancer incidence.

30 to 65 Years Option 1: Cervical Cytology Alone ; Option 2: High-Risk HPV (hrHPV) Alone ; Option 3: Co-Testing (Cytology + hrHPV) Cytology: Every 3 Years ; hrHPV Alone: Every 5 Years ; Co-Testing: Every 5 Years All three strategies are endorsed by USPSTF, ACOG, and ASCCP. Primary hrHPV alone every 5 years with an FDA-approved assay provides superior sensitivity compared to cytology alone and avoids redundant co-testing costs.

>65 Years Discontinue Screening (if adequate prior negative screening documented) Cessation Criteria for cessation: 3 consecutive negative cytology results OR 2 consecutive negative co-tests/hrHPV tests within the past 10 years, with the most recent test performed within the past 5 years.

Post-Hysterectomy Discontinue Screening (if cervix removed and no high-grade history) Cessation If total hysterectomy (cervix removed) for benign indications and no history of CIN 2+ in past 25 years . If supracervical hysterectomy (cervix intact), continue routine screening.

Important

The 25-Year CIN 2+ Exception: Women with a documented history of treated or untreated high-grade precancerous cervical lesions ( CIN 2, CIN 3, or adenocarcinoma in situ [AIS] ) must continue routine age-appropriate cervical screening for a minimum of 25 years after diagnosis and treatment, even if this surveillance extends beyond 65 years of age or occurs following total hysterectomy (vaginal cuff cytology every 3 years).